News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab, Inc. (GEN.CO), Roche (RHHBY) Drug Reduces Damage to Heart Muscle During Angioplasty


3/11/2013 8:19:28 AM

A single dose of the investigational anti-inflammatory inclacumab, developed by Roche and Genmab, considerably reduces damage to heart muscle during angioplasty. That was the conclusion of a Phase II trial, the data for which has been presented at the American College of Cardiology meeting in San Francisco. The 530-patient study, led by Jean-Claude Tardif of the University of Montreal, compared the effects of one of two doses of inclacumab, an antibody that blocks P-selectin, a molecule that drives inflammation and plays an important role in vascular disease, with placebo. Patients were randomised to receive an infusion of inclacumab at 20 mg/kg or 5 mg/kg or placebo one to 24 hours before angioplasty.Dr Tardif and his team then measured the subjects' levels of troponin I, which is a marker used clinically to diagnose heart attack.


comments powered by Disqus
Genmab, Inc.
Roche
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES